Illumina's Upcoming Q3 2025 Financial Results Announcement

Illumina Plans to Release Q3 2025 Financial Results
Illumina, Inc. (NASDAQ: ILMN) is set to announce its third quarter 2025 financial results after the market closes on Thursday, October 30, 2025. This quarterly announcement is an important event for investors, analysts, and stakeholders who track the company’s performance in the biotech sector.
Conference Call Scheduled
On the same day, the company's Chief Executive Officer, Jacob Thaysen, PhD, alongside Chief Financial Officer Ankur Dhingra, will conduct a conference call to go over the quarter's financial and operational outcomes. The call is scheduled to start at 1:30 PM Pacific Time, which is equivalent to 4:30 PM Eastern Time.
Details for Joining the Conference Call
Those interested in participating in the call can find access through the Investor Info section on Illumina's official website. It is highly encouraged to join the call at least ten minutes prior to the commencement time for a seamless experience.
Replay Availability
For those who cannot join the live call, a recording will be made available on the Illumina website post-event. The replay can be accessed for a minimum of 30 days, ensuring that all interested parties can stay updated on the company's developments.
About Illumina
Illumina is a pioneer in genomic technology, dedicated to advancing human health by harnessing the power of the genome. With a robust portfolio of DNA sequencing and array-based products, Illumina serves diverse markets, including research, clinical applications, oncology, and reproductive health. Their innovations play a crucial role in various fields, such as agriculture and other emerging sectors.
To further understand the company’s impact on healthcare and technology, it’s beneficial to explore their advancements in genomics. Illumina continues to lead in providing sophisticated solutions that are critical for both therapeutic and diagnostic uses.
Investors and Media Contacts
Investors may reach out to Conor McNamara at +1.858.291.6421 for any inquiries or further information. For media-related questions, Christine Douglass is the contact point.
Frequently Asked Questions
What are Illumina's plans for the Q3 2025 financial results?
Illumina plans to announce its Q3 2025 financial results on October 30, 2025, following market closure.
Who will be hosting the financial results conference call?
The conference call will be hosted by CEO Jacob Thaysen and CFO Ankur Dhingra.
How can I access the Illumina conference call?
Participants can join the conference call through the Investor Info section on Illumina's website.
Will there be a replay of the conference call?
Yes, a replay will be available on Illumina's website for at least 30 days after the live call.
What is Illumina's mission in the genomics industry?
Illumina aims to improve human health by leveraging genomic data and technological innovations, making significant advances across various sectors.
About The Author
Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.